Article Figures & Data
Figures
- Fig. 1.
Immunohistochemical labeling patterns of dCK protein in resected pancreatic cancer tissues. Examples of 1+ staining (A), 2+ staining (B), and 3+ staining (C). In all cases, note the presence of positive labeling lymphocytes within the desmoplastic stroma that serve as a useful internal control for evaluating the intensity of dCK immunolabeling.
- Fig. 2.
Kaplan-Meier survival curves in relation to dCK immunolabeling status. Low levels of dCK immunolabeling show a significant relationship toward shorter overall survival (A) and survival following gemcitabine (B).
- Fig. 3.
dCK immunolabeling patterns in an untreated primary infiltrating pancreatic cancer (A) and a matched lung metastasis that developed two years later following gemcitabine therapy (B). Strong positive (3+) immunolabeling of the nucleus and cytoplasm is seen within the neoplastic cells of the untreated primary tumor. In contrast, a significant reduction in dCK immunolabeling (1+) was found in the metastatic disease from this patient (original magnification, ×200).
Tables
- Table 1.
dCK primer sequences
Exon Sequence Product size (bp) 5′-Untranslated region/1 Forward 5′-CAGGTCAGGATCTGGCTTAG-3′ 208 Reverse 5′-GAAGGGAACATCGGTAAGGA-3′ 2 Forward 5′-ATTGGGCAGGGAGCCTTTTC-3′ 646 Reverse 5′-CTATTTGGGAGGATATATGC-3′ 3 Forward 5′-GGAAAGAGTATGAGAAAGGGAAC-3′ 387 Reverse 5′-CTTGTACGTGGCCATTTGAA-3′ 4 Forward 5′-CTGCTTTCCACGGCACTATG-3′ 618 Reverse 5′-GAATCCCAGACTGGGCAAGT-3′ 5 Forward 5′-GCCACCAAGTGGCTGAAAAG-3′ 485 Reverse 5′-GCAATGAGATCCTATTTAC-3′ 6 Forward 5′-TTGGGCTCCATATGGTAAATC-3′ 508 Reverse 5′-GAATCTCAGAATCTGACAGAT-3′ 7 Forward 5′-CAATGGCATTGTGGTAGTTAC-3′ 418 Reverse 5′-GAAATGTAGAGGTAGATGGTT-3′ - Table 2.
Clinicopathologic features of patients treated with gemcitabine
Low dCK High dCK P Age (y) 70.3 ± 8.1 59.8 ± 7.4 <0.0006 Gender (M/F) 3/6 17/6 <0.04 Race (white/black) 8/1 20/3 NS Tumor differentiation* Well/moderate (n = 12) 4 8 NS Poor (n = 10) 2 8 Positive margins* Yes (n = 3) 1 2 NS No (n = 18) 4 14 Clinical stage I 0 2 NS II 3 1 III 5 14 IV 1 6 CA19-9 decrease ≥ 25% Yes (n = 7) 3 4 NS No (n = 15) 2 13 Overall survival (mo) 14.6 ± 7.3 21.7 ± 13.8 <0.009 Overall survival following gemcitabine initiation (mo) 10.0 ± 5.3 12.0 ± 9.3 <0.04 Gemcitabine single agent Yes (n = 11) 3 8 NS No (n = 21) 6 15 ↵* This information was only available for patients who underwent surgical resection.
Volume 12, Issue 8
